Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial -

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial
Information type: Randomised controlled trials
Source: JAMA Psychiatry
Specialities: Mental health and illness | Nutritional and metabolic disorders
Summary
RCT (n=304) failed to replicate findings of original single-centre trial as it found no evidence of efficacy for ω-3 PUFAs plus cognitive behavioural case management [CBCM] vs. placebo plus CBCM in transition to psychosis status at 6 months (6.7 vs. 5.1%, respectively).
UKMi comment
An editorial notes that although ω-3 PUFA treatment is attractive for prevention from a pathophysiologic perspective and because of its benign adverse effect profile, its preventive efficacy for psychosis had been demonstrated in only 1 single-site study (n= 81); the results of which have not been confirmed in this current study. Two additional multisite studies of ω-3 PUFAs are underway to further clarify its role in the prevention of psychosis.
Related links: Editorial